author-photo

Bikramjit Chopra

GlaxoSmithKline

5

Papers

71

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

2020 Blood
Show All
- Source
- Cite
- Save
Citations (9)
DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (20)
DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

2020 Blood
Show All
- Source
- Cite
- Save
Citations (16)
Phase I/II, open-label, 2-arm study to evaluate safety, tolerability, and clinical activity of GSK2857916 in combination with 2 standard-of-care (SoC) regimens in relapsed/refractory multiple myeloma: (DREAMM 6).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in ADA-SCID

2018 Orphanet Journal of Rare Diseases
Show All
- Source
- Cite
- Save
Citations (22)